C. Boutros

4.6k total citations · 2 hit papers
22 papers, 1.6k citations indexed

About

C. Boutros is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, C. Boutros has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in C. Boutros's work include Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (8 papers) and Melanoma and MAPK Pathways (5 papers). C. Boutros is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), CAR-T cell therapy research (8 papers) and Melanoma and MAPK Pathways (5 papers). C. Boutros collaborates with scholars based in France, United States and Australia. C. Boutros's co-authors include Caroline Robert, Christine Mateus, Émilie Routier, Émilie Lanoy, Jean‐Charles Soria, Matthieu Texier, Stéphane Champiat, Aurélien Marabelle, Olivier Lambotte and Alexander M.M. Eggermont and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

C. Boutros

22 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

2016 813 citations C. Boutros, Ahmad A. Tarhini et al. Nature Reviews Clinical Oncology profile →
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

2015 503 citations Camille Hua, Lise Boussemart et al. JAMA Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Boutros France	9	1.3k	556	304	285	105	22	1.6k
Matthieu Texier France	12	1.3k 1.0×	567 1.0×	321 1.1×	266 0.9×	108 1.0×	31	1.7k
Jérôme Biton France	22	1.1k 0.9×	1.1k 2.0×	516 1.7×	421 1.5×	111 1.1×	35	2.2k
Gro Wiedswang Norway	20	1.1k 0.8×	265 0.5×	338 1.1×	374 1.3×	145 1.4×	38	1.7k
Steffen Ormanns Germany	20	1.0k 0.8×	428 0.8×	315 1.0×	486 1.7×	163 1.6×	70	1.6k
Lucia Festino Italy	18	880 0.7×	375 0.7×	190 0.6×	368 1.3×	69 0.7×	39	1.2k
Ryusuke Murakami Japan	19	1.2k 1.0×	952 1.7×	324 1.1×	606 2.1×	98 0.9×	78	2.3k
Parisa Momtaz United States	14	1.5k 1.1×	499 0.9×	362 1.2×	353 1.2×	150 1.4×	40	1.8k
Antonella Argentiero Italy	23	794 0.6×	406 0.7×	326 1.1×	596 2.1×	162 1.5×	48	1.6k
Lorenza Di Guardo Italy	15	987 0.8×	398 0.7×	248 0.8×	360 1.3×	75 0.7×	48	1.2k
Pierre Combe France	13	916 0.7×	473 0.9×	432 1.4×	373 1.3×	74 0.7×	42	1.5k

Countries citing papers authored by C. Boutros

Since Specialization

Citations

This map shows the geographic impact of C. Boutros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Boutros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Boutros more than expected).

Fields of papers citing papers by C. Boutros

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Boutros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Boutros. The network helps show where C. Boutros may publish in the future.

Co-authorship network of co-authors of C. Boutros

This figure shows the co-authorship network connecting the top 25 collaborators of C. Boutros. A scholar is included among the top collaborators of C. Boutros based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Boutros. C. Boutros is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boutros, C., et al.. (2024). Progress in Immune Checkpoint Inhibitor for Melanoma Therapy. Hematology/Oncology Clinics of North America. 38(5). 997–1010. 2 indexed citations

Boutros, C., et al.. (2023). Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma. Current Oncology Reports. 25(9). 989–996. 7 indexed citations

Hamid, Omid, Anthony M. Joshua, Antoni Ribas, et al.. (2020). 1139P Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma. Annals of Oncology. 31. S762–S763. 2 indexed citations

Poels, Kikkie, Mandy M. T. van Leent, C. Boutros, et al.. (2020). Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis. JACC CardioOncology. 2(4). 599–610. 101 indexed citations

Boutros, C., Nathalie Chaput, Émilie Lanoy, et al.. (2020). Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma. Journal for ImmunoTherapy of Cancer. 8(2). e000627–e000627. 15 indexed citations

Tawbi, Hussein A., C. Boutros, David L. Kok, Caroline Robert, & Grant A. McArthur. (2018). New Era in the Management of Melanoma Brain Metastases. American Society of Clinical Oncology Educational Book. 38(38). 741–750. 49 indexed citations

Boutros, C., Christine Mateus, Émilie Lanoy, et al.. (2017). A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab in patients (pts) with metastatic melanoma.. Journal of Clinical Oncology. 35(15_suppl). 9549–9549. 2 indexed citations

Boutros, C., Émilie Routier, Camille Hua, et al.. (2016). Detailed safety profile of the anti-PD-1 monoclonal antibody pembrolizumab in 78 consecutive patients (pts) with advanced melanoma. Annals of Oncology. 27. vi385–vi385. 1 indexed citations

Boutros, C., Christine Mateus, Émilie Routier, et al.. (2016). A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab (Ipi) in patients (pts) with metastatic melanoma. Annals of Oncology. 27. vi383–vi383. 2 indexed citations

10.

Bluthgen, M.V., et al.. (2016). Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. Lung Cancer. 99. 111–116. 22 indexed citations

11.

Boutros, C., Ahmad A. Tarhini, Émilie Routier, et al.. (2016). Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology. 13(8). 473–486. 813 indexed citations breakdown →

12.

Izzedine, Hassan, Christine Mateus, C. Boutros, et al.. (2016). Renal effects of immune checkpoint inhibitors. Nephrology Dialysis Transplantation. 32(6). 936–942. 78 indexed citations

13.

Kossaï, Myriam, Boris Duchemann, C. Boutros, et al.. (2015). Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer. 89(3). 306–310. 8 indexed citations

14.

Boutros, C., Chafika Mazouni, F. Lerebours, et al.. (2015). A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer. British Journal of Cancer. 112(6). 992–997. 8 indexed citations

15.

Hua, Camille, Lise Boussemart, Christine Mateus, et al.. (2015). Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatology. 152(1). 45–45. 503 indexed citations breakdown →

16.

Boutros, C., et al.. (2013). 115P ORAL ETOPOSIDE IN PRETREATED ADVANCED THYMOMA AND THYMIC CARCINOMA. A FRENCH EXPERIENCE. Lung Cancer. 80. S49–S50. 2 indexed citations

17.

Kossaï, Myriam, Boris Duchemann, Caroline Caramella, et al.. (2013). Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development program (phase I trials) at Institut Gustave Roussy.. Journal of Clinical Oncology. 31(15_suppl). 7604–7604. 2 indexed citations

18.

Wagner, Mathilde, Joaquim Bellmunt, C. Boutros, et al.. (2012). False Positive 2-18Fluroro-deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients With Disseminated Seminoma and Post-Chemotherapy Residual Masses. Clinical Genitourinary Cancer. 11(1). 66–69. 4 indexed citations

19.

Kattan, Joseph, C. Boutros, Fadi Farhat, et al.. (2012). Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer. Journal of Cancer. 3. 362–368. 2 indexed citations

20.

Ghosn, Marwan, et al.. (2010). Experience with palliative care in patients with advanced cancer at a tertiary care hospital in a developing country. Supportive Care in Cancer. 19(4). 573–575. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact